Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of hemophilia A.
Patients previously treated for Hemophilia A.
Patients without previous history of inhibitors or patients with previous history of inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry.
No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor.
Initiation of or currently on damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis).
Signed informed consent/assent.
You may not be if
Concurrent participation in an investigational program with interventions outside of routine clinical practice.
Diagnosis of any other bleeding/coagulation disorder other than hemophilia A.
Contra-indications according to the local marketing authorization.
Patient on immune tolerance induction (ITI) treatment at the time of enrollment.
Clareo Health | Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
